NCT06630221 2025-07-03Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 MutationsCase Comprehensive Cancer CenterPhase 2 Recruiting25 enrolled
NCT02010645 2020-01-02Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer CenterPhase 2 Terminated6 enrolled 8 charts